Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial.

Cox MC, Castiello L, Mattei M, Santodonato L, D'Agostino G, Muraro E, Martorelli D, Lapenta C, Di Napoli A, Di Landro F, Cangemi M, Pavan A, Castaldo P, Hohaus S, Donati S, Montefiore E, Berdini C, Carlei D, Monque DM, Ruco L, Prosperi D, Tafuri A, Spadaro F, Sestili P, Spada M, Dolcetti R, Santini SM, Rozera C, Aricò E, Capone I, Belardelli F.

Clin Cancer Res. 2019 Sep 1;25(17):5231-5241. doi: 10.1158/1078-0432.CCR-19-0709. Epub 2019 Jun 6.

PMID:
31171545
2.

Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.

Rozera C, Cappellini GA, D'Agostino G, Santodonato L, Castiello L, Urbani F, Macchia I, Aricò E, Casorelli I, Sestili P, Montefiore E, Monque D, Carlei D, Napolitano M, Rizza P, Moschella F, Buccione C, Belli R, Proietti E, Pavan A, Marchetti P, Belardelli F, Capone I.

J Transl Med. 2015 May 2;13:139. doi: 10.1186/s12967-015-0473-5.

3.

A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.

Torelli GF, Rozera C, Santodonato L, Peragine N, D'agostino G, Montefiore E, Napolitano MR, Monque DM, Carlei D, Mariglia P, Pauselli S, Gozzer M, Bafti MS, Girelli G, Guarini A, Belardelli F, Foà R.

Blood Transfus. 2015 Jul;13(3):464-71. doi: 10.2450/2015.0231-14. Epub 2015 Jan 30.

4.

Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases.

Toschi E, Sgadari C, Malavasi L, Bacigalupo I, Chiozzini C, Carlei D, Compagnoni D, Bellino S, Bugarini R, Falchi M, Palladino C, Leone P, Barillari G, Monini P, Ensoli B.

Int J Cancer. 2011 Jan 1;128(1):82-93. doi: 10.1002/ijc.25550.

5.

The use of HAART for biological tumour therapy.

Monini P, Toschi E, Sgadari C, Bacigalupo I, Palladino C, Carlei D, Barillari G, Ensoli B.

J HIV Ther. 2006 Sep;11(3):53-6. Review. No abstract available.

PMID:
17580499
6.

A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice.

Buffa V, Negri DR, Leone P, Bona R, Borghi M, Bacigalupo I, Carlei D, Sgadari C, Ensoli B, Cara A.

J Gen Virol. 2006 Jun;87(Pt 6):1625-34.

PMID:
16690927
7.

Type I IFN protects permissive macrophages from Legionella pneumophila infection through an IFN-gamma-independent pathway.

Schiavoni G, Mauri C, Carlei D, Belardelli F, Pastoris MC, Proietti E.

J Immunol. 2004 Jul 15;173(2):1266-75.

8.

[HIV protease inhibitors for the treatment of Kaposi's sarcoma].

Grosso G, Sgadari C, Barillari G, Toschi E, Bacigalupo I, Carlei D, Palladino C, Baccarini S, Malavasi L, Moracci G, Leone P, Chiozzini C, Monini P, Ensoli B.

Recenti Prog Med. 2003 Feb;94(2):69-74. Review. Italian.

PMID:
12908373
9.

Treatment of Kaposi's sarcoma--an update.

Toschi E, Sgadari C, Monini P, Barillari G, Bacigalupo I, Palladino C, Baccarini S, Carlei D, Grosso G, Sirianni MC, Ensoli B.

Anticancer Drugs. 2002 Nov;13(10):977-87. Review.

PMID:
12439331
10.

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.

Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P, Ensoli B.

Nat Med. 2002 Mar;8(3):225-32.

PMID:
11875492
11.

Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor.

Toschi E, Barillari G, Sgadari C, Bacigalupo I, Cereseto A, Carlei D, Palladino C, Zietz C, Leone P, Stürzl M, Buttò S, Cafaro A, Monini P, Ensoli B.

Mol Biol Cell. 2001 Oct;12(10):2934-46.

12.

Mechanism of paclitaxel activity in Kaposi's sarcoma.

Sgadari C, Toschi E, Palladino C, Barillari G, Carlei D, Cereseto A, Ciccolella C, Yarchoan R, Monini P, Stürzl M, Ensoli B.

J Immunol. 2000 Jul 1;165(1):509-17.

13.

Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response.

Rozera C, Carlei D, Lollini PL, De Giovanni C, Musiani P, Di Carlo E, Belardelli F, Ferrantini M.

Am J Pathol. 1999 Apr;154(4):1211-22.

14.

Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F.

J Clin Invest. 1998 Jan 15;101(2):429-41.

15.

Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-alpha and HSVtk: perspectives for the generation of cancer vaccines.

Santodonato L, D'Agostino G, Santini SM, Carlei D, Musiani P, Modesti A, Signorelli P, Belardelli F, Ferrantini M.

Gene Ther. 1997 Nov;4(11):1246-55.

Supplemental Content

Loading ...
Support Center